SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer
BackgroundFluorouracil (FU)-based chemotherapy regimens are indispensable in the comprehensive treatment of colorectal cancer (CRC). However, the heterogeneity of treated individuals and the severe adverse effects of chemotherapy results in limited overall benefit.MethodsFirstly, Weighted gene co-ex...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.873871/full |
| _version_ | 1818237019955920896 |
|---|---|
| author | Siyuan Weng Siyuan Weng Siyuan Weng Zaoqu Liu Zaoqu Liu Zaoqu Liu Xiaofeng Ren Hui Xu Hui Xu Hui Xu Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yuqing Ren Yuyuan Zhang Qin Dang Long Liu Chunguang Guo Richard Beatson Jinhai Deng Xinwei Han Xinwei Han Xinwei Han |
| author_facet | Siyuan Weng Siyuan Weng Siyuan Weng Zaoqu Liu Zaoqu Liu Zaoqu Liu Xiaofeng Ren Hui Xu Hui Xu Hui Xu Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yuqing Ren Yuyuan Zhang Qin Dang Long Liu Chunguang Guo Richard Beatson Jinhai Deng Xinwei Han Xinwei Han Xinwei Han |
| author_sort | Siyuan Weng |
| collection | DOAJ |
| description | BackgroundFluorouracil (FU)-based chemotherapy regimens are indispensable in the comprehensive treatment of colorectal cancer (CRC). However, the heterogeneity of treated individuals and the severe adverse effects of chemotherapy results in limited overall benefit.MethodsFirstly, Weighted gene co-expression network analysis (WGCNA) identified modules tightly associated with chemotherapy response. Then, the in-house cohort and prognostic cohorts from TCGA and GEO were subjected to Cox proportional hazards model and survival analysis to ascertain the predictable function of SCG2 on the prognosis of CRC patients. Finally, we performed In vitro experiments, functional analysis, somatic mutation, and copy number variation research to explore the biological characteristics of SCG2.ResultsWe identified red and green as the modules most associated with chemotherapy response, in which SCG2 was considered a risky factor with higher expression predicting poorer prognosis. SCG2 expression in the APC non-mutation group was remarkably higher than in the mutation group. The mutation frequencies of amplified genes differed significantly between different SCG2 expression subgroups. Besides, CRC cell lines with SCG2 knockdown have reduced invasive, proliferative, and proliferative capacity. We discovered that the SCG2 high expression subgroup was the immune hot type and considered more suitable for immunotherapy.ConclusionThis study demonstrates the clinical significance and biological characteristics of SCG2, which could serve as a promising biomarker to identify patients who may benefit from chemotherapy and immunotherapy. |
| first_indexed | 2024-12-12T12:19:07Z |
| format | Article |
| id | doaj.art-a1410210f94b4db1b2d816b70393aef9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T12:19:07Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a1410210f94b4db1b2d816b70393aef92022-12-22T00:24:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.873871873871SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal CancerSiyuan Weng0Siyuan Weng1Siyuan Weng2Zaoqu Liu3Zaoqu Liu4Zaoqu Liu5Xiaofeng Ren6Hui Xu7Hui Xu8Hui Xu9Xiaoyong Ge10Xiaoyong Ge11Xiaoyong Ge12Yuqing Ren13Yuyuan Zhang14Qin Dang15Long Liu16Chunguang Guo17Richard Beatson18Jinhai Deng19Xinwei Han20Xinwei Han21Xinwei Han22Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaFaculty of Engineering and Information Technology University of Technology Sydney, Sydney, NSW, AustraliaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaKing’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Cancer Centre, London, United Kingdom0Richard Dimbleby Laboratory of Cancer Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United KingdomDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaBackgroundFluorouracil (FU)-based chemotherapy regimens are indispensable in the comprehensive treatment of colorectal cancer (CRC). However, the heterogeneity of treated individuals and the severe adverse effects of chemotherapy results in limited overall benefit.MethodsFirstly, Weighted gene co-expression network analysis (WGCNA) identified modules tightly associated with chemotherapy response. Then, the in-house cohort and prognostic cohorts from TCGA and GEO were subjected to Cox proportional hazards model and survival analysis to ascertain the predictable function of SCG2 on the prognosis of CRC patients. Finally, we performed In vitro experiments, functional analysis, somatic mutation, and copy number variation research to explore the biological characteristics of SCG2.ResultsWe identified red and green as the modules most associated with chemotherapy response, in which SCG2 was considered a risky factor with higher expression predicting poorer prognosis. SCG2 expression in the APC non-mutation group was remarkably higher than in the mutation group. The mutation frequencies of amplified genes differed significantly between different SCG2 expression subgroups. Besides, CRC cell lines with SCG2 knockdown have reduced invasive, proliferative, and proliferative capacity. We discovered that the SCG2 high expression subgroup was the immune hot type and considered more suitable for immunotherapy.ConclusionThis study demonstrates the clinical significance and biological characteristics of SCG2, which could serve as a promising biomarker to identify patients who may benefit from chemotherapy and immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.873871/fullcolorectal cancerchemotherapyprognosisimmunotherapybiomarker |
| spellingShingle | Siyuan Weng Siyuan Weng Siyuan Weng Zaoqu Liu Zaoqu Liu Zaoqu Liu Xiaofeng Ren Hui Xu Hui Xu Hui Xu Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yuqing Ren Yuyuan Zhang Qin Dang Long Liu Chunguang Guo Richard Beatson Jinhai Deng Xinwei Han Xinwei Han Xinwei Han SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer Frontiers in Immunology colorectal cancer chemotherapy prognosis immunotherapy biomarker |
| title | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer |
| title_full | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer |
| title_fullStr | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer |
| title_full_unstemmed | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer |
| title_short | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer |
| title_sort | scg2 a prognostic marker that pinpoints chemotherapy and immunotherapy in colorectal cancer |
| topic | colorectal cancer chemotherapy prognosis immunotherapy biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.873871/full |
| work_keys_str_mv | AT siyuanweng scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT siyuanweng scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT siyuanweng scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT zaoquliu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT zaoquliu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT zaoquliu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xiaofengren scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT huixu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT huixu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT huixu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xiaoyongge scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xiaoyongge scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xiaoyongge scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT yuqingren scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT yuyuanzhang scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT qindang scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT longliu scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT chunguangguo scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT richardbeatson scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT jinhaideng scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xinweihan scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xinweihan scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer AT xinweihan scg2aprognosticmarkerthatpinpointschemotherapyandimmunotherapyincolorectalcancer |